At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 105 enrolled
Drug / intervention
Nivolumab +2 moredrug
Likely dose
Nivolumab 480mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Ipilimumab for Non-small Cell Lung Cancer. Completed, enrolled 105 participants across 12 sites.
Detailed Summary
This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with unresectable stage III NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Big Ten Cancer Research Consortium
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedSep 2017
Primary CompletionOct 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedSep 18, 2017
Enrollment StartSep 15, 2017
Primary CompletionOct 13, 2023
Study CompletionFeb 6, 2024
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 8.8 years ago
Interventions
Nivolumabdrug
480mg
Nivolumabdrug
240mg
Ipilimumabdrug
1mg/kg